ASCO 2017: Efficacy of cabazitaxel rechallenged in heavily-treated patients with metastatic castration-resistant prostate cancer (mCRPC)
Chicago, IL (UroToday.com) While docetaxel (DOC) has long been the primary chemotherapy option for the management of castration-resistant prostate cancer (CRPC), cabazitaxel (CABA) has established itself as a second-line therapeutic option.1 However, introduction of novel agents targeting the androgen receptor axis have provided competing options for physicians and patients.
ASCO 2017: Efficacy, safety, tolerability, and pharmacokinetics of EPI-506 (ralaniten acetate), a novel androgen receptor N-terminal domain (NTD) inhibitor, in men with metastatic castration-resistant prostate cancer progressing after enzalutamide and/or
Chicago, IL (UroToday.com) While the introduction of enzalutamide (Enza) and abiraterone (Abi) have revolutionized the management of castration-resistant prostate cancer (CRPC), the influx of drugs targeted the androgen axis has subsequently led to the identification of new resistance mechanisms.1 The androgen-receptor variants (ARV), specifically ARV-7, are variants in which the ligand-binding domain is typically lost, resulting in a constitutively active AR, independent of androgens.
ASCO 2017: Rovalpituzumab tesirine as a therapeutic agent for Neuroendocrine Prostate Cancer
Chicago, IL (UroToday.com) Neuroendocrine prostate cancer (NEPC) represents a rare subtype of prostate cancer. NEPC represent a histologic subtype of prostate cancer that demonstrate low to absent AR expression and often have neuroendocrine features, and thus have low PSA production. As such, it may represent clinical progression and resistance to traditional therapies.
ASCO 2017: Real-world outcomes in second-line treatment of metastatic castration-resistant prostate cancer: The Prostate Cancer Registry
Chicago, IL (UroToday.com) In this multi-institutional study, the authors utilize the Prostate Cancer Registry, to examine outcomes of patients with metastatic castration-resistant prostate cancer (mCRPC) who have undergone second-line therapy. The Prostate Cancer Registry is a prospective, international observational study that began in June 2013. It is the first prospective international registry for metastatic prostate cancer. Its goal is to assess the characteristics and management of > 3000 mCRPC patients (pts) in routine clinical practice for ≤ 3 years.
ASCO 2017: Whole exome sequencing of circulating tumor DNA (ctDNA) in patients with neuroendocrine prostate cancer informs tumor heterogeneity
Chicago, IL (UroToday.com) The authors of this study previously published a manuscript identifying the divergent clonal evolution of castration-resistant prostate cancer (CRPC) to a neuroendocrine prostate cancer histology (NEPC).1 NEPC represent a histologic subtype of prostate cancer that demonstrate low to absent AR expression and often have neuroendocrine features, and thus have low PSA production. Progression to NEPC histology may represent a mechanism of resistance.
ASCO 2017: Development and validation of a prognostic model for overall survival in chemotherapy-naive men with metastatic castration-resistant prostate cancer from the phase 3 Prevail clinical trial
Chicago, IL (UroToday.com) While the AFFIRM trial1 introduced enzalutamide (Enza) as a treatment for castration-resistant prostate cancer (CRPC) that had failed docetaxel chemotherapy, the PREVAIL study2,3 helped move it to the front-line for newly castrate-resistant patients, particularly in patients with lower volume metastatic disease. However, both enzalutamide and abiraterone have an approximately 20-30% primary resistance rate. Due to the cost and potential adverse events of this medication, better patient selection will help reduce unnecessary treatment. However, better understanding outcomes of all metastatic castration-resistant prostate cancer (mCRPC) is also important.
ASCO 2017: BRCA1/2 reversion mutations in prostate cancer identified from clinical tissue and liquid biopsy samples
Chicago, IL (UroToday) Next generation sequencing was utilized to analyze DNA (>50 ng from FFPE or blood samples) from 2284 patients with metastatic prostate cancer, specifically looking for genomic alterations (GAs) such base substitutions, indels, rearrangements, and copy number changes. RevGA were any GA that could restore the reading frame.